Journal
CANCERS
Volume 13, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/cancers13112543
Keywords
inflammatory breast cancer; immunotherapy; immune checkpoint inhibitors; tumor microenvironment; tumor immunology
Categories
Funding
- Veterans Affairs Merit Award [I01BX004903]
- NIH [F30CA236031]
- UIC Award for Graduate Research
- University of Illinois College of Medicine Craig Research Fellowship
- Career Scientist Award [IK6 BX004855]
Ask authors/readers for more resources
Inflammatory breast cancer (IBC) is a rare and aggressive subtype of breast cancer with poor prognosis. Despite the success of immunotherapy in other difficult-to-treat cancers, progress in utilizing immunotherapy for IBC has been challenging.
Simple Summary Despite recent advances in the treatment of other breast cancer subtypes, inflammatory breast cancer (IBC) remains a significant clinical challenge, with an overall 5-year survival rate of 39%. Though immunotherapy has shown remarkable efficacy in other difficult-to-treat cancers, such approaches have yet to show substantial therapeutic efficacy in IBC. Here, we summarize the known immune composition of IBC tumors, as well as past and present efforts to advance immunotherapy in the treatment of IBC. Inflammatory breast cancer (IBC) is a rare and aggressive subtype of breast cancer that carries a particularly poor prognosis. Despite the efficacy of immunotherapy in other difficult to treat forms of breast cancer, progress for immunotherapy in IBC has been difficult. Though immunotherapy has been under clinical investigation in IBC since the 1970s, few approaches have shown significant therapeutic efficacy, and no immunotherapy regimens are currently used in the treatment of IBC. Here, we provide a comprehensive summary of what is known about the immune composition of IBC tumors, clinical and basic science evidence describing the role for immune checkpoints such as PD-L1 in IBC pathobiology, as well as past and present attempts to advance ICIs in the treatment of IBC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available